Reply to Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

Leung Henry W. C.; Leung John-Hang; Chan Agnes L. F.

首页> 外文期刊>Expert opinion on drug safety >Reply to Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

【24h】

Reply to Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

机译：回复致编辑的信：HER2针对性药物作为转移性HER2阳性乳腺癌的一线治疗的疗效和安全性：网络META分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Expert opinion on drug safety》 |2018年第12期|共1页
作者
Leung Henry W. C.; Leung John-Hang; Chan Agnes L. F.;
展开▼
作者单位

China Med Univ An Nan Hosp Dept Radiat Oncol Tainan Taiwan;

China Med Univ An Nan Hosp Dept Pharm Tainan Taiwan;

China Med Univ An Nan Hosp Dept Pharm Tainan Taiwan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药品;
关键词

相似文献

外文文献
中文文献
专利

1. Reply to Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis [J] . Leung Henry W. C., Leung John-Hang, Chan Agnes L. F. Expert opinion on drug safety . 2018,第7a12期

机译：回复致编辑的信：HER2针对性药物作为转移性HER2阳性乳腺癌的一线治疗的疗效和安全性：网络META分析
2. Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis [J] . Feng Fubin, Yin Fang, Zhang Tingting, Expert opinion on drug safety . 2018,第7a12期

机译：致编辑的信：HER2针对性药物作为转移性HER2阳性乳腺癌的一线治疗的疗效和安全性：网络元分析
3. Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis [J] . H.W.C.a, Leung, J.-H.b, Expert opinion on drug safety . 2018,第1a6期

机译：HER2-靶向剂组合作为转移HER2阳性乳腺癌的一线治疗的疗效和安全性：网络元分析
4. Efficacy and safety of Qi-Boosting Toxin-Resolving formulae for breast cancer: a meta-analysis [C] . Liang Zhou, Lixin Liang, Zhijun Zeng, International Conference on Biological Information and Biomedical Engineering . 2019

机译：乳腺癌毒素分辨式疗效和安全性的疗效和安全性：META分析
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Efficacy and safety of targeted therapy for metastatic HER2-positive breast cancer in the first-line treatment: a Bayesian network meta-analysis [O] . Fubin Feng, Tingting Zhang, Fang Yin, 2019

机译：一线治疗转移性HER2阳性乳腺癌靶向治疗的疗效和安全性：贝叶斯网络荟萃分析
7. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results [O] . Edith A. Perez, José Manuel López-Vega, Thierry Petit, 2016

机译：长春瑞滨联合培妥珠单抗和曲妥珠单抗联合治疗HER2阳性局部晚期或转移性乳腺癌患者的一线治疗的安全性和有效性：VELVET研究组1的最终结果

Reply to Letter to the editor: efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

著录项

相似文献

相关主题

期刊订阅